DK3445354T3 - AZELAIC ACID ESTERS IN THE TREATMENT OF INSULIN RESISTANCE - Google Patents
AZELAIC ACID ESTERS IN THE TREATMENT OF INSULIN RESISTANCE Download PDFInfo
- Publication number
- DK3445354T3 DK3445354T3 DK17786579.7T DK17786579T DK3445354T3 DK 3445354 T3 DK3445354 T3 DK 3445354T3 DK 17786579 T DK17786579 T DK 17786579T DK 3445354 T3 DK3445354 T3 DK 3445354T3
- Authority
- DK
- Denmark
- Prior art keywords
- treatment
- acid esters
- insulin resistance
- azelaic acid
- azelaic
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/225—Polycarboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Diabetes (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Dermatology (AREA)
- Endocrinology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662325381P | 2016-04-20 | 2016-04-20 | |
| PCT/US2017/028417 WO2017184767A1 (en) | 2016-04-20 | 2017-04-19 | Azelaic acid esters in the treatment of insulin resistance |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3445354T3 true DK3445354T3 (en) | 2022-08-29 |
Family
ID=60088670
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK17786579.7T DK3445354T3 (en) | 2016-04-20 | 2017-04-19 | AZELAIC ACID ESTERS IN THE TREATMENT OF INSULIN RESISTANCE |
Country Status (19)
| Country | Link |
|---|---|
| US (3) | US10251857B2 (en) |
| EP (2) | EP3445354B8 (en) |
| JP (2) | JP7072762B2 (en) |
| KR (1) | KR102233912B1 (en) |
| CN (1) | CN109195597B (en) |
| AU (2) | AU2017253088B2 (en) |
| CA (1) | CA3021516C (en) |
| DK (1) | DK3445354T3 (en) |
| ES (1) | ES2925775T3 (en) |
| HR (1) | HRP20220988T1 (en) |
| HU (1) | HUE059844T2 (en) |
| LT (1) | LT3445354T (en) |
| NZ (1) | NZ746669A (en) |
| PL (1) | PL3445354T3 (en) |
| PT (1) | PT3445354T (en) |
| RS (1) | RS63558B1 (en) |
| SG (1) | SG11201808367UA (en) |
| SI (1) | SI3445354T1 (en) |
| WO (1) | WO2017184767A1 (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI3445354T1 (en) * | 2016-04-20 | 2022-10-28 | New Frontier Labs, Llc | Azelaic acid esters in the treatment of insulin resistance |
| IL295663A (en) * | 2020-02-19 | 2022-10-01 | New Frontier Labs Llc | Azelaic acid esters in the treatment or prevention of dyslipidemia and associated conditions |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2426683A1 (en) * | 1974-06-01 | 1975-12-18 | Boehringer Mannheim Gmbh | BIGUANID AND METHOD FOR MANUFACTURING THEREOF |
| US5594015A (en) * | 1994-06-22 | 1997-01-14 | Regents Of The University Of California | Thiazolidine derivatives for the treatment of psoriasis |
| WO2001012786A1 (en) * | 1999-08-16 | 2001-02-22 | Human Genome Sciences, Inc. | Retinoid receptor interacting polynucleotides, polypeptides, and antibodies |
| US6627223B2 (en) * | 2000-02-11 | 2003-09-30 | Eurand Pharmaceuticals Ltd. | Timed pulsatile drug delivery systems |
| ATE454895T1 (en) * | 2001-08-13 | 2010-01-15 | Univ Yale | METHOD FOR INDUCING A SELECTIVELY SUPPRESSED IMMUNE RESPONSE |
| US7149574B2 (en) * | 2003-06-09 | 2006-12-12 | Palo Alto Investors | Treatment of conditions through electrical modulation of the autonomic nervous system |
| US20080051373A1 (en) * | 2003-07-31 | 2008-02-28 | The Board Of Regents Of The University Of Texas System | Parenteral preparations of GI-safer phospholipid-associated anti-inflammatories and methods of preparation and use |
| WO2006074379A2 (en) | 2005-01-07 | 2006-07-13 | Azaya Therapeutics, Inc. | Methods and compositions involving esters of azelaic acid and other dicarboxylic acids |
| US8440217B1 (en) * | 2005-06-15 | 2013-05-14 | Mawaheb M. EL-Naggar | Method and system with contact lens product for treating and preventing adverse eye conditions |
| EP1909766B1 (en) * | 2005-07-28 | 2016-03-16 | Shire LLC | PHARMACEUTICAL FORMULATIONS/COMPOSITIONs OF GUANFACINE SUITABLE FOR SINGLE DAILY DOSE |
| US7713929B2 (en) * | 2006-04-12 | 2010-05-11 | Biodel Inc. | Rapid acting and long acting insulin combination formulations |
| US8093017B2 (en) * | 2005-12-07 | 2012-01-10 | Siemens Heathcare Diagnostics Inc. | Detection of soluble adiponectin receptor peptides and use in diagnostics and therapeutics |
| ES2390620T3 (en) * | 2008-03-10 | 2012-11-14 | Nestec S.A. | Medium chain dicarboxylic acids and their derivatives and metabolic disorders |
| US20090326069A1 (en) * | 2008-06-30 | 2009-12-31 | Bltn, Llc | Azelaic acid ester compositions and methods for diagnosing and treating tissue conditions using azelaic acid ester compositions and proteinaceous biomarkers |
| US20120251525A1 (en) * | 2009-06-30 | 2012-10-04 | Streeper Robert T | Method of utilizing azelaic acid esters to modulate communications mediated by biological molecules |
| US9023887B2 (en) * | 2011-04-15 | 2015-05-05 | University of Pittsburgh—of the Commonwealth System of Higher Education | Lipase inhibitors for the treatment of pancreatitis and organ failure |
| KR101593539B1 (en) * | 2015-07-03 | 2016-02-15 | 고려대학교 산학협력단 | Composition of Azelaic Acid Having Adipose Triglyceride Hydrolysis effect |
| SI3445354T1 (en) * | 2016-04-20 | 2022-10-28 | New Frontier Labs, Llc | Azelaic acid esters in the treatment of insulin resistance |
-
2017
- 2017-04-19 SI SI201731210T patent/SI3445354T1/en unknown
- 2017-04-19 ES ES17786579T patent/ES2925775T3/en active Active
- 2017-04-19 JP JP2018552655A patent/JP7072762B2/en active Active
- 2017-04-19 EP EP17786579.7A patent/EP3445354B8/en active Active
- 2017-04-19 PL PL17786579.7T patent/PL3445354T3/en unknown
- 2017-04-19 US US15/491,937 patent/US10251857B2/en active Active
- 2017-04-19 NZ NZ746669A patent/NZ746669A/en unknown
- 2017-04-19 HU HUE17786579A patent/HUE059844T2/en unknown
- 2017-04-19 CA CA3021516A patent/CA3021516C/en active Active
- 2017-04-19 PT PT177865797T patent/PT3445354T/en unknown
- 2017-04-19 HR HRP20220988TT patent/HRP20220988T1/en unknown
- 2017-04-19 DK DK17786579.7T patent/DK3445354T3/en active
- 2017-04-19 SG SG11201808367UA patent/SG11201808367UA/en unknown
- 2017-04-19 RS RS20220773A patent/RS63558B1/en unknown
- 2017-04-19 EP EP22175016.9A patent/EP4085907A1/en active Pending
- 2017-04-19 CN CN201780024922.8A patent/CN109195597B/en active Active
- 2017-04-19 LT LTEPPCT/US2017/028417T patent/LT3445354T/en unknown
- 2017-04-19 WO PCT/US2017/028417 patent/WO2017184767A1/en active Application Filing
- 2017-04-19 AU AU2017253088A patent/AU2017253088B2/en active Active
- 2017-04-19 KR KR1020187033326A patent/KR102233912B1/en active IP Right Grant
-
2019
- 2019-02-04 US US16/267,338 patent/US11026912B2/en active Active
-
2021
- 2021-03-01 JP JP2021031730A patent/JP7088460B2/en active Active
- 2021-05-12 US US17/318,586 patent/US20210260014A1/en active Pending
-
2022
- 2022-06-02 AU AU2022203809A patent/AU2022203809B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3334422T3 (en) | USE OF CANNABIDIOLIC ACID IN THE TREATMENT OF EPILEPSY | |
| DK3341482T3 (en) | ARTIFICIAL NUCLEIC ACID MOLECULES | |
| DK3233130T3 (en) | NUCLEIC ACID CONSTRUCTIONS AND GENERATIVE VECTORS FOR USE IN THE TREATMENT OF WILSON DISEASE | |
| DK3294325T3 (en) | ENHANCEMENT OF THE EFFECT OF CAR-MANIPULATED T CELLS USING NUCLEIC ACID VACCINATION | |
| DK3206715T3 (en) | USE OF CANNABIDIOL IN THE TREATMENT OF TUBEROUS SCLEROSE COMPLEX | |
| DK3185957T3 (en) | Patisiran for use in the treatment of transthyretin-mediated amyloidosis | |
| DK3811943T3 (en) | Compound for use in the treatment of eye disorders | |
| DK3481846T3 (en) | 11-SUBSTITUTED 24-HYDROXYSTEROLS FOR USE IN THE TREATMENT OF NMDA-RELATED CONDITIONS | |
| DK3197472T3 (en) | RECOMBINANT PHE-FREE PROTEINS FOR USE IN THE TREATMENT OF PHENYLKETONURI | |
| DK3882250T3 (en) | TETRAHYDROPYRANYL-AMINO-PYRROLOPYRIMIDINONE FOR USE IN THE TREATMENT OF BTK-MEDIATED DISORDERS | |
| DK3307296T3 (en) | TIMP2 FOR USE IN THE TREATMENT OF AGING ASSOCIATED CONDITIONS | |
| DK3391902T3 (en) | PLASMINOGEN FOR USE IN THE TREATMENT OF DIABETIC ANGIOCARDIOPATHY | |
| DK3456330T3 (en) | CORTEXOLON-17ALPHA-VALERAT FOR USE IN TUMOR TREATMENT | |
| DK3556383T3 (en) | Plasminogen for use in the treatment of diabetes | |
| DK3297654T3 (en) | TREATMENT OF POST-BARIATRIC HYPOGLYCHEMISTRY WITH EXENDIN (9-39) | |
| MA46284A (en) | HEART CANNULA | |
| DK3302519T3 (en) | ORNITHODOROS-MOUBATA-COMPLEMENT-INHIBITOR FOR USE IN THE TREATMENT OF ACUTE GRAFT-VERSUS-HOST DISEASE | |
| DK3374497T3 (en) | MODIFIED MACROPHAGE FOR USE IN THE TREATMENT OF CANCER | |
| FI20155123A (en) | RACK WITH AUTO RETURN AND AUTO RETURN METHOD FOR THE SAME | |
| DK3149049T3 (en) | IL-22 FOR USE IN THE TREATMENT OF METABOLISM DISEASES | |
| DK3423060T3 (en) | Imatinib for use in the treatment of stroke | |
| DK3389653T3 (en) | 2-IMINOBIOTIN FOR USE IN THE TREATMENT OF BRAIN CELL LESION | |
| DK3406258T3 (en) | MEDICINE FOR USE FOR THE TREATMENT OF URINARY ACID | |
| DK3331853T3 (en) | Selected amide of hydroxybutanoic acid and its uses in the treatment of alcohol abuse | |
| DK3164123T3 (en) | Novel uses of benzylideneguanidine derivatives in the treatment of proteopathies |